Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.

Salvatore PaiellaGiuseppe MalleoIvana CataldoClizia GaspariniMatteo De PastenaGiulia De MarchiGiovanni MarchegianiBorislav RusevAldo ScarpaRoberto GirelliAlessandro GiardinoIsabella FrigerioMirko D'OnofrioErica SecchettinClaudio BassiRoberto Salvia

Published in: Langenbeck's archives of surgery (2017)

Within patients undergoing RFA for LAPC, SMAD4 analysis could segregate a subgroup of subjects with improved survival, who likely benefited from tumor ablation.

Keyphrases

radiofrequency ablation
patients undergoing
end stage renal disease
epithelial mesenchymal transition
transforming growth factor
chronic kidney disease
ejection fraction
peritoneal dialysis
clinical trial
phase iii
patient reported outcomes
catheter ablation